--- title: "Jefferies Remains a Buy on AstraZeneca (AZN)" type: "News" locale: "en" url: "https://longbridge.com/en/news/305865876.md" description: "Jefferies analyst Michael Leuchten maintained a Buy rating on AstraZeneca today and set a price target of £175.00.According to TipRanks, Leuchten is an analyst with an average return of -3.1% and a 54.65% success rate. Leuchten covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Roche Holding AG.In addition to Jefferies, AstraZeneca also received a Buy from Bernstein’s Justin Smith in a report issued on November 3. However, on November 6, Deutsche Bank maintained a Hold rating on AstraZeneca (LSE: AZN)." datetime: "2026-11-17T19:25:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/305865876.md) - [en](https://longbridge.com/en/news/305865876.md) - [zh-HK](https://longbridge.com/zh-HK/news/305865876.md) generator: "portal-rs" --- # Jefferies Remains a Buy on AstraZeneca (AZN) Jefferies analyst Michael Leuchten maintained a Buy rating on AstraZeneca today and set a price target of £175.00. According to TipRanks, Leuchten is an analyst with an average return of -3.1% and a 54.65% success rate. Leuchten covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Roche Holding AG. In addition to Jefferies, AstraZeneca also received a Buy from Bernstein’s Justin Smith in a report issued on November 3. However, on November 6, Deutsche Bank maintained a Hold rating on AstraZeneca (LSE: AZN). ### Related Stocks - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md) - [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md) - [DB.US](https://longbridge.com/en/quote/DB.US.md) - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) ## Related News & Research - [AstraZeneca's sonesitatug vedotin gets FDA priority review for advanced gastric cancers](https://longbridge.com/en/news/306076537.md) - [AZ beefs up myasthenia gravis pedigree with US, EU Klygefa nods](https://longbridge.com/en/news/305697522.md) - [AstraZeneca fends off lawsuit over alleged Soliris drug monopoly](https://longbridge.com/en/news/305701830.md) - [AstraZeneca secures FDA approval for Imfinzi combo in MIBC](https://longbridge.com/en/news/305649865.md) - [AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy](https://longbridge.com/en/news/305633730.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**